D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Benzinga2024/12/11 22:41

Enlivex Therapeutics Receives Regulatory Authorization From Israeli Ministry Of Health For Initiation Of Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis

Benzinga2024/12/11 21:32

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients With TMJ Osteoarthritis

GlobeNewswire2024/12/11 21:30

Enlivex Therapeutics Analyst Ratings

Benzinga2024/12/03 22:35

Elivex Therapeutics Shares Are Trading Higher After the Company Announced Interim Efficacy Data Showing Statistical Significance and Marked Improvements for Its Allocetra Trial.

Benzinga2024/12/03 22:14

Enlivex Announces Interim Efficacy Data From Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis; The Interim Efficacy Results Are Statistically Significant, And Show Marked Improvements In All Key Efficacy Endpoints, Including...

Benzinga2024/12/03 21:32